New treatment for blood diseases, such as leukemia and lymphoma.
HemoGenyx has raised $393K in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2026.
HemoGenyx's investors include Prevail Partners, 43North, ScaleReady, Mint Capital.
HemoGenyx is headquartered in London, United Kingdom.
New treatment for blood diseases, such as leukemia and lymphoma.
HemoGenyx is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HemoGenyx — Funding & Investors." VCBacked, September 3, 2026, https://www.vcbacked.co/company/hemogenyx. Accessed November 14, 2026.
VCBacked. (2026). HemoGenyx — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/hemogenyx
{{cite web |title=HemoGenyx — Funding & Investors |url=https://www.vcbacked.co/company/hemogenyx |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at HemoGenyx? Request a listing update